Possible Coronavirus Vaccines Successful in Preclinical Testing in Italy
RIO DE JANEIRO, BRAZIL – Preclinical testing of candidates for the novel coronavirus (Sars-CoV-2) vaccine in Italy proved positive. In an interview with ANSA news agency on Friday, April 10th, Luigi Aurisicchio, CEO of the Roman company Takis Biotech, which is conducting studies with five vaccines, said there was “strong antibody production” with a single dose.
“The first results in the pre-clinical models have shown strong immunogenicity of vaccine candidates,” said Aurisicchio, adding that two of them appear more promising. Final results are expected by mid-May, and testing in humans could begin in September.
All five vaccines are based on a technology called electroporation, which consists of an electrical impulse in the muscle to increase the permeability of cell membranes. They were obtained from genetic materials corresponding to different parts of the spike protein, which the virus uses to attack cells and multiply.
According to the Civil Defense, Italy counts 147,577 cases of the novel coronavirus and 18,849 deaths, but the numbers have been decelerating for some weeks as a result of isolation measures.
More: Brazil news in English, every day from The Rio Times.
This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error